Background Anti-C1q autoantibodies can disrupt normal complement function, contributing to the formation of pathogenic immune ...

Background Lupus nephritis (LN) is the most serious complication of SLE. Interstitial fibrosis is the dominant pathological ...

Background Systemic lupus erythematosus (SLE) is uncommon after the age of 50. The aim of this study was to determine clinical, biological and immunological characteristics of late-onset SLE. Patients ...

Objective Celastrol is a bioactive constituent extracted from Tripterygium wilfordii (thunder god vine). It has been demonstrated to have a therapeutic effect on experimental disease models for ...

CD19-directed chimeric antigen receptor (CAR) T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for patients with autoimmune diseases.

Objective To evaluate the effect of early belimumab administration on disease progression in patients with early active SLE. Methods This multicentre observational study included patients with early ...

Objectives Even in a lupus low disease activity state (LLDAS), many patients with SLE continue to face residual symptoms and disease burden. We aimed to evaluate the quality of life, activity ...

Objective To investigate the effects of Qihuang Jianpi Zishen Granules (QJZG) on renal injury in SLE mice, focusing on macrophage M1/M2 polarisation mediated by the AMPK/ULK1 signalling pathway.

Each year the Lupus Science & Medicine editorial team selects the most meritorious research papers to receive the Lupus Science & Medicine Paper of the Year Award. Primary considerations are the ...

Wang Xiang, Yaoyao Tang, Xiuzhi Jia, Yuewen Lu, Xinxin Zhang, Xiaolei Shi, Jianwen Yu, Hongjian Ye, Zhong Zhong, Jiang Lanping, Xi Xia, Ruihan Tang, Wei Chen ...

Objective SLE affects multiple organs and is associated with increased mortality and organ damage. While treatment recommendations for non-renal SLE stratify by disease activity, no standard approach ...